Abivax repurchases $90M royalty certificates, issues $45M ADS offering, extending cash runway to Q4 2027.

Abivax announced the repurchase of $90 million in royalty certificates, paying $45 million in cash and $45 million via a vendor loan set off by a $45 million American Depositary Shares (ADS) offering priced at $111.57 per ADS. This move reduces royalty obligations, simplifies the capital structure, and enhances financial flexibility. The company maintains a strong cash position with a runway into Q4 2027, supporting ongoing clinical programs and pre-commercial activities. The offering will dilute shares by approximately 0.5% and is expected to close around May 7, 2026.